Puma Biotechnology Inc (NAS:PBYI)
$ 4.94 -0.195 (-3.8%) Market Cap: 238.30 Mil Enterprise Value: 251.28 Mil PE Ratio: 15.44 PB Ratio: 4.66 GF Score: 59/100

Puma Biotechnology Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 11, 2021 / 06:50PM GMT
Release Date Price: $11.12 (+2.58%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang. I'm midcap biotech analysts at the Barclays.

Welcome to our Second Virtual Global Healthcare Conference. First, I wish everyone staying healthy, and I would like to thank all the participants, investors, companies and especially our event team and corporate access team, who made this virtual health care conference possible.

With that, I would like to introduce our next presenter, Alan Auerbach, Chief Executive Officer from Puma Biotech. Alan, I hand over to you.

Alan H. Auerbach
Puma Biotechnology, Inc. - Founder, Chairman, President, CEO & Secretary

Great. Thank you. So first of all, I would just like to welcome everyone to the Puma Biotechnology presentation. As a reminder, I'll be making forward-looking statements.

So on this slide, you can see our product pipeline for the company. We have one drug that we have brought into the company, which is neratinib, and we have it on the market in 2 indications and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot